EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of a highly oversubscribed Series A Preferred Financing round led by Broadline Capital, a global private equity investment firm. EndoSphere Inc., which holds 23 U.S. and international issued and pending patents, will use the funding to expand its intellectual property assets and to complete additional clinical product testing. Continue Reading Article at PR Newswire >>
U.S. Patent number 7,931,693 titled "Method and Apparatus for Reducing Obesity" describes a noninvasive device that uses the body's natural physiology to regulate appetite and satiety among other potential uses.
"This strong initial patent position, in combination with significant clinical interest, makes EndoSphere an attractive partner in the rapidly growing fields of interventional gastroenterology and obesity treatments," commented James McKinley, EndoSphere CEO. Continue Reading
Article at PR Newswire >>
"We are extremely pleased to welcome three very distinguished individuals to the board of EndoSphere,” said James McKinley, CEO. “These gentlemen will add significant discipline, experience and expertise to our company’s strategic leadership and governance."
Christopher Thorne is the founder and managing partner of Broadline Capital, a global private equity investment firm. Continue Reading Article at PR Newswire >>
OneMedForum today announced that Christopher Thorne, the managing partner of Broadline Capital and chairman of EndoSphere Inc., is the “featured speaker” at OneMedForum NY 2011’s China dinner event. The forum convenes institutional investors and executives of healthcare and life science companies from around the world. This conference is the sixth OneMedForum, and second held in New York. Continue Reading Article at PR
Amol Soin, M.D. and Stephen R. Haynes appointed as advisors to the company.Continue Reading Article at PR
EndoSphere Inc., a medical technology company that holds 25 issued and pending U.S. and international patents, today announced that the U.S. Patent and Trademark Office has issued the company a new strategic patent containing numerous claims relating to its incisionless antiobesity device technologies. Continue Reading Article at PR Newswire >>
EndoSphere Inc. today announced that it received CE Mark regulatory approval for the Satisphere™ System, a noninvasive device for the treatment for obesity – one of the world’s largest health issues. The Satisphere device improves regulation of appetite and satiety by using the body’s natural physiology. The endoscopically-insertable device is completely incisionless, reversible, and repeatable. Continue Reading Article at PR Newswire >>
EndoSphere Inc. today announced that the Innovation Ohio Loan Fund (IOLF) has awarded $1 million to support EndoSphere’s platform of noninvasive, endoscopically-implantable devices that treat metabolic diseases including obesity and type 2 diabetes. Continue Reading Article at PR
Today EndoSphere was selected as this year’s Fierce 15 Award Winner, named by FierceMedicalDevices. The “Fierce 15” list identifies “the most promising privately-held medical device companies in the world”. The award was announced live today onstage at the Boston Convention and Exhibition Center during AdvaMed 2012, one of the medtech industry’s largest events. Continue Reading Article at PR
EndoSphere Inc. is pleased to announce that it has been selected to present at the 15th Annual MedTech Investing (MTI) Europe Conference, which will take place September 19th - 20th at the Kings Fund in London. MTI Europe is the premier and longest-running medtech industry partnering event in Europe according to Campden Conferences.Continue Reading Article at PR Newswire >>
EndoSphere Inc. is pleased to announce that it has been selected to present at MDB Capital Group’s prestigious 3rd Annual Bright Lights Conference, which will take place September 9th - 11th at the New York Palace Hotel in New York City. EndoSphere will be presenting on Tuesday, September 11, 2012.Continue Reading Article at PR